Home > Insider Trading > Filing (0001209191-21-023868)

Filing Details

Accession Number:: 0001209191-21-023868
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-03-31 19:11:39
Reporting Period:: 2021-03-30

Accepted Time:: 2021-03-31 19:11:39
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1710072	Edgewise Therapeutics Inc.	EWTX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1357522	A. Peter Thompson	C/O Edgewise Therapeutics, Inc. 3145 Colorado Ave. Boulder CO 80303		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-03-30	12,730,036	$0.00	13,046,956	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2021-03-30	272,724	$0.00	272,724	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2021-03-30	46,875	$16.00	319,599	No	4	P	Indirect	See Footnotes
Common Stock	Acquisiton	2021-03-30	312,500	$16.00	13,359,456	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnotes
No	4	C	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2021-03-30	8,187,100	$0.00	8,187,100	$0.00
Common Stock	Series B-1 Preferred Stock	Disposition	2021-03-30	1,572,960	$0.00	1,572,960	$0.00
Common Stock	Series B-2 Preferred Stock	Disposition	2021-03-30	1,301,626	$0.00	1,301,626	$0.00
Common Stock	Series C Preferred Stock	Disposition	2021-03-30	1,668,350	$0.00	1,668,350	$0.00
Common Stock	Series C Preferred Stock	Disposition	2021-03-30	272,724	$0.00	272,724	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock and Series C Preferred Stock converted into one share of the Issuer's Common Stock immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.
These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationship, OrbiMed Advisors and GP VI may be deemed to have voting power and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VI.
These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationship, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by Genesis.